Valeo Pharma Inc.



Nano One Materials Corp.
Latest Comments
image_pdfimage_print

Valeo Pharma’s Redesca™ rollout is progressing rapidly, proving the value of its business model, as its revenue grows 280% in Q3, 2021

Valeo Pharma Inc. (CSE: VPH | OTCQB: VPHIF | FSE: VP2) (“Valeo”) is a specialty pharmaceutical marketing company dedicated to […]


Steve Saviuk on Valeo Pharma’s Redesca, an injectable anticoagulant drug that just commenced shipment in Canada

In a recent InvestorIntel interview, Tracy Weslosky spoke with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB: […]


Valeo Pharma launches Redesca™ and is forecasting company revenues to increase 20x by 2025

Bringing new pharmaceutical products to market is a long and expensive process. One Canadian company has found an innovative way […]


Welcome to the Big Leagues.

Valeo Pharma Inc. (CSE: VPH | OTCQB: VPHIF) has taken a big step forward in its business development with yesterday’s […]


Revenue is forecast to triple, Valeo Pharma has 10 products in their portfolio

COVID-19 continues to be a huge global problem with global cases now over 112 million. Vaccines are a source of […]


Valeo Pharma’s Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19

In a new InvestorIntel interview Tracy Weslosky speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB: […]


Revenue Forecasted to Triple as Valeo Benefits from Last Year’s Successes

Valeo Pharma Inc. (CSE: VPH | OTC: VPHIF |FSE: VP2) is a specialty pharmaceutical company and its revenue is expected […]